The absolute value of lymphocyte counts and the response to decitabine treatment in patients with myelodysplastic syndrome

Yan-Bin PANG; Song-Ying ZHAO; Hua XUE; Hui-Mei GUO; Luo-Ming HUA; Li-Xia FAN; Jian-Min LUO; Xin DU.
Medical Journal of Chinese People's Liberation Army ; (12): 239-243, 2018.
Artículo en Zh | WPRIM | ID: wpr-694106

Documentos relacionados

  1. [Predicting Therapeutic Response by Lymphocyte Level at 28th Day after DAC Treatment in Patients with MDS].
  2. The effect of decitabine-combined minimally myelosuppressive regimen bridged allo-HSCT on the outcomes of pediatric MDS from 10 years' experience of a single center.
  3. Cladribine- and decitabine-containing conditioning regimen has a low post-transplant relapse rate in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
  4. Evaluation of Reduced-Dose Decitabine and Azacitidine for Treating Myelodysplastic Syndromes: A Retrospective Study.